Navigation Links
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
Date:1/22/2008

Phase II Investigational Trial Published in CANCER: the Journal of the

American Cancer Society

SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) announced today that results of a phase II clinical study, published in the journal CANCER demonstrate that the addition of radioimmunotherapy (RIT) to chemotherapy for previously untreated patients with non-follicular indolent non-Hodgkin's lymphoma (NHL) was both well tolerated and effective, producing a 100 percent complete remission at end of treatment with an estimated 89 percent of patients remaining in remission at three years.

The study, conducted at the Institute of Hematology and Medical Oncology at University of Bologna, Italy, investigated the use of a single dose of Zevalin(R) (Ibritumomab Tiuxetan) as consolidation therapy following treatment with a regimen of fludarabine and mitoxantrone (FM chemotherapy) among 26 patients with newly diagnosed non-follicular indolent NHL. Non-follicular lymphomas are also referred to as intermediate grade compared to the low grade follicular or high grade diffuse B cell variety. FM chemotherapy resulted in 50 percent of patients achieving a complete remission (CR) and 30 percent achieving a partial remission (PR). Of the 20 patients (13 with CR and 7 with PR) who were evaluable for Zevalin consolidation, 100 percent obtained a CR at the end of treatment. With a median follow up of 20 months, the estimated three-year progression free survival (PFS) was 89.5 percent. The most common greater than or equal to grade 3 toxicities included neutropenia (11 patients) and thrombocytopenia (16 patients).

"This single arm, non-randomized phase II trial provides addition
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
2. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
3. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. SGX Initiates Phase I Trials for SGX523
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  eHealth, electronic access ... and access of this information, has become a ... however, that has not translated into user-friendly, effective ... Photo - http://photos.prnewswire.com/prnh/20140929/149123 ... few years developing MWD® Health Manager iEHR, a ...
(Date:9/30/2014)... Sept. 30, 2014  RFID Journal announced today that registration ... www.rfidjournalevents.com/healthcare ), the premier industry event focused on the ... care sector. The conference and exhibition will be held ... Place in Chicago, Ill. ... executives explaining how they use RFID to improve asset-utilization ...
(Date:9/30/2014)... , Sept. 30, 2014  Come fall, many ... "who" or "what" they want to be for Halloween. ... their look with decorative contact lenses bought without a ... of year that people purchase and wear contact lenses ... 2013 American Eye-Q ® consumer survey, 17 percent ...
Breaking Medicine Technology:MWD Challenges the Big eHealth Players With New Software for Your Smartphone 2Hear New Case Studies from Industry Leaders at RFID in Health Care 2014 2Hear New Case Studies from Industry Leaders at RFID in Health Care 2014 3The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3
... WIRE)--May 15, 2007 - Synthetic Blood,International, Inc. ... analysis of its Phase IIa study with ... line with preliminary,study results announced in December ... of increasing patients' oxygen,tension levels compared with ...
... WIRE)--May 17, 2007 - Salix,Pharmaceuticals, Ltd. (NASDAQ:SLXP) today ... the Company's products,will be presented at Digestive Disease ... Digestive Disease Week is considered the,largest and most ... Every year it attracts more than 16,000 physicians,researchers ...
Cached Medicine Technology:Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5
(Date:9/30/2014)... (PRWEB) September 30, 2014 OZ Naturals ... selling beauty brand on Amazon.com. , “The majority of ... respective beauty categories on Amazon.com,” said Craig Romero, CEO of ... UK on Amazon.co.uk and Canada on Amazon.ca , Romero went ... just launched earlier last month, are already taking over top ...
(Date:9/30/2014)... Central and the University of Michigan are pleased to ... journal, Clinical Diabetes and Endocrinology , which is ... the first quarter of 2015. , The journal ... Medicine, in the Division of Metabolism, Endocrinology, and Diabetes, ... regarded Associate Editors and an international Editorial Board. ...
(Date:9/30/2014)... cannot multiply and cardiac muscles contain few stem ... after a heart attack. Now Tel Aviv University ... in cardiac tissue engineering. , Dr. Tal Dvir ... Department of Biotechnology, Department of Materials Science and ... been developing sophisticated micro- and nanotechnological tools ...
(Date:9/30/2014)... Four scientists at Cold Spring Harbor Laboratory (CSHL) ... two new CSHL grants announced in Washington today. The ... the National Institutes of Health (NIH), totaling $46 million ... funding for the BRAIN Initiative. , ... launched by the President in the spring of 2013. ...
(Date:9/30/2014)... September 30th, 2014 A new report launched ... (The Irish Longitudinal Study on Ageing) conducted by ... Trinity College Dublin, Ireland, has highlighted the serious, ... Ireland,s intellectual disability population. , The IDS-TILDA study ... Europe and the only one in the world ...
Breaking Medicine News(10 mins):Health News:OZ Naturals Now the No. 1 Selling Beauty Brand on Amazon.com 2Health News:OZ Naturals Now the No. 1 Selling Beauty Brand on Amazon.com 3Health News:BioMed Central to publish open access journal in collaboration with the University of Michigan 2Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:4 Cold Spring Harbor Laboratory scientists will contribute to President Obama's BRAIN Initiative under new NIH grants 2Health News:4 Cold Spring Harbor Laboratory scientists will contribute to President Obama's BRAIN Initiative under new NIH grants 3Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 3Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 4
... of a woman diagnosed with breast cancer is 63, so ... older patient population. But older women with breast cancer are ... the effects of chemotherapy used in addition to other therapies ... May 14 issue of The New England Journal of ...
... (NYSE Alternext US: ADL), a US-based pharmaceutical company with ... into two distinct five-year marketing and distribution agreements with ... provider, whereby GenWay Biotech will ... the US and Canada. The partnership significantly advances ...
... award winning mobile health care solution - OnCare by Gearworks - will ... Association of America (VNAA) 27th Annual Meeting from May 14-16, 2009 in ... ... -- Gearworks , a leading provider of location-based mobile business applications, ...
... WASHINGTON, May 13 "On behalf of the 157,000 ... I would like to thank Congressman Mike Simpson for ... -- a resolution yesterday congratulating the ADA on its ... vigilant on behalf of its members, the ADA nonetheless ...
... XLHealth, owner and operator of Care Improvement Plus, one ... Needs Plans, views the Social Security and Medicare Trustees ... address the needs of the chronically ill. Along with ... timeline toward Medicare insolvency includes spending associated with chronically ...
... American Nurses Pledges Support for Legislation SILVER SPRING, Md., ... vowed support for legislation that will protect nurses from ... Health Care Worker Protection Act of 2009 (H.R. 2381), ... to develop and implement a standard to eliminate manual ...
Cached Medicine News:Health News:Study shows chemotherapy improves survival among older breast cancer patients 2Health News:AMDL, Inc. Enters Into Distribution Agreements With GenWay Biotech, Inc. to Advance Commercialization of the DR-70 (FDP) Cancer Test in the US and Canada 2Health News:AMDL, Inc. Enters Into Distribution Agreements With GenWay Biotech, Inc. to Advance Commercialization of the DR-70 (FDP) Cancer Test in the US and Canada 3Health News:AMDL, Inc. Enters Into Distribution Agreements With GenWay Biotech, Inc. to Advance Commercialization of the DR-70 (FDP) Cancer Test in the US and Canada 4Health News:Gearworks to Exhibit OnCare at VNAA 27th Annual Meeting 2Health News:Gearworks to Exhibit OnCare at VNAA 27th Annual Meeting 3Health News:Statement by American Dental Association President John S. Findley on Passage of H.Res. 204, a Congressional Resolution Congratulating the Association for its 150 Years of Service 2Health News:XLHealth Statement on Social Security and Medicare Trustees Report 2Health News:Common-Sense Patient Handling Bill Protects Patients and Nurses 2
Polyester ribbon impregnated with conjugated Protein G - .13 OD per sq. cm....
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... glass (1.5x) Gonio lens will enable visualization ... 4 mirror lens is the industry preferred ... and features : , Crispest, clearest ... previously unattainable with Gonio lenses., 4 equally ...
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: